On May 10, 2022 K-Medi Hub reported that it signed a business agreement with Eisen Science for research on the development of innovative new drugs using artificial intelligence (Press release, AIGEN Sciences, MAY 10, 2022, View Source [SID1234643555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this agreement, K-Medi Hub and Igen Science plan to focus their research on finding effective substances for new drug development and discovering lead substances through compound optimization.

Eisen Science is a bio venture established last year based on the technological capabilities of the DMIS research team in the Department of Computer Science at Korea University. It has an artificial intelligence platform for new drug development based on cell-level transcriptome data.

Through the new drug development optimization technology support project, K-Medi Hub continues to support research gaps for basic research results in the development of promising new drugs with high risks for domestic small and medium-sized ventures.

In particular, we have recently developed a platform that can significantly reduce the time and cost required to develop innovative new drugs by utilizing artificial intelligence and are providing it on a public portal site.